A COMPARATIVE STUDY ON THE EFFICACY OF INTRALESIONAL MMR VACCINE AND INTRALESIONAL PURIFIED PROTEIN DERIVATIVE IN VERRUCA VULGARIS

SHUNMADHI0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.30 patients aged 12-25 years with verruca vulgaris(less than 20 in number) attending the Dermatology OPD during the study period.
•2.Patient who has not undergone any prior systemic or topical treatment.
•3.Those who are giving consent to participate in the study.
•4.Those who are willing for follow up.

•1.Prior known allergic response to MMR vaccine
•2.Patients who received any other treatments for their warts before enrolment.
•3.Patients with H/O asthma,allergic skin disorders, meningitis or convulsions
•4. Patient with acute febrile illness or signs of any inflammation or infection.
•5.Patients with Hepatitis B & Hepatitis C infection
•6. Patients with immunosuppression/ HIV Infection
•7.Patients with anogenital warts
•8.Patients with H/O TB
•9.Induration measuring < 5 mm at 48 hours of Tuberculin skin test and MMR skin test.

发起方

SHUNMADHI